Brain Health: Translating Scientific Evidence Into Clinical Practice in Multiple Sclerosis

Brain volume loss (BVL) progresses more rapidly in patients with multiple sclerosis (MS) than in healthy individuals, and brain atrophy begins early in the course of the disease. The objective of this symposium was to emphasise the importance of care and preservation of the brain within treatment pr...

Full description

Bibliographic Details
Main Authors: Per Soelberg Sørensen, Wiendl, Andreas Lysandropoulos, Andrew Chan
Format: Article
Language:English
Published: European Medical Journal 2016-07-01
Series:European Medical Journal Neurology
Subjects:
EAN
Online Access:http://emjreviews.com/wp-content/uploads/Brain-Health-Translating-Scientific-Evidence-Into-Clinical-Practice-in-Multiple-Sclerosis.pdf
id doaj-87d5153c102e43039b58cf506ce4fd7f
record_format Article
spelling doaj-87d5153c102e43039b58cf506ce4fd7f2020-11-24T23:10:34ZengEuropean Medical JournalEuropean Medical Journal Neurology2054-45292016-07-01413644 Brain Health: Translating Scientific Evidence Into Clinical Practice in Multiple SclerosisPer Soelberg Sørensen0Wiendl1Andreas Lysandropoulos,2Andrew Chan3Danish Multiple Sclerosis Center, Copenhagen University Hospital, Copenhagen, Denmark Department of Neurology, University Hospital of Münster, Münster, Germany Neuroimmunology Unit, Department of Neurology, University Hospital Erasme, Brussels, Belgium Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, GermanyBrain volume loss (BVL) progresses more rapidly in patients with multiple sclerosis (MS) than in healthy individuals, and brain atrophy begins early in the course of the disease. The objective of this symposium was to emphasise the importance of care and preservation of the brain within treatment protocols for MS so that early and appropriate management can be initiated to preserve brain volume and function. Prof Per Solberg Sørensen chaired the symposium and welcomed the speakers. Prof Heinz Wiendl gave a presentation on BVL in MS and described its underlying pathophysiology. Dr Andreas Lysandropoulos illustrated how information on BVL is clinically relevant and can be taken from clinical studies to assist clinical practice and decision-making. The final presentation was given by Prof Andrew Chan who highlighted the important role of brain atrophy in decision-making for early treatment and presented recent data for two treatments for MS: teriflunomide and the monoclonal antibody alemtuzumab. The symposium was concluded by a short question and answer session.http://emjreviews.com/wp-content/uploads/Brain-Health-Translating-Scientific-Evidence-Into-Clinical-Practice-in-Multiple-Sclerosis.pdfEANEuropean Association of Neurology
collection DOAJ
language English
format Article
sources DOAJ
author Per Soelberg Sørensen
Wiendl
Andreas Lysandropoulos,
Andrew Chan
spellingShingle Per Soelberg Sørensen
Wiendl
Andreas Lysandropoulos,
Andrew Chan
Brain Health: Translating Scientific Evidence Into Clinical Practice in Multiple Sclerosis
European Medical Journal Neurology
EAN
European Association of Neurology
author_facet Per Soelberg Sørensen
Wiendl
Andreas Lysandropoulos,
Andrew Chan
author_sort Per Soelberg Sørensen
title Brain Health: Translating Scientific Evidence Into Clinical Practice in Multiple Sclerosis
title_short Brain Health: Translating Scientific Evidence Into Clinical Practice in Multiple Sclerosis
title_full Brain Health: Translating Scientific Evidence Into Clinical Practice in Multiple Sclerosis
title_fullStr Brain Health: Translating Scientific Evidence Into Clinical Practice in Multiple Sclerosis
title_full_unstemmed Brain Health: Translating Scientific Evidence Into Clinical Practice in Multiple Sclerosis
title_sort brain health: translating scientific evidence into clinical practice in multiple sclerosis
publisher European Medical Journal
series European Medical Journal Neurology
issn 2054-4529
publishDate 2016-07-01
description Brain volume loss (BVL) progresses more rapidly in patients with multiple sclerosis (MS) than in healthy individuals, and brain atrophy begins early in the course of the disease. The objective of this symposium was to emphasise the importance of care and preservation of the brain within treatment protocols for MS so that early and appropriate management can be initiated to preserve brain volume and function. Prof Per Solberg Sørensen chaired the symposium and welcomed the speakers. Prof Heinz Wiendl gave a presentation on BVL in MS and described its underlying pathophysiology. Dr Andreas Lysandropoulos illustrated how information on BVL is clinically relevant and can be taken from clinical studies to assist clinical practice and decision-making. The final presentation was given by Prof Andrew Chan who highlighted the important role of brain atrophy in decision-making for early treatment and presented recent data for two treatments for MS: teriflunomide and the monoclonal antibody alemtuzumab. The symposium was concluded by a short question and answer session.
topic EAN
European Association of Neurology
url http://emjreviews.com/wp-content/uploads/Brain-Health-Translating-Scientific-Evidence-Into-Clinical-Practice-in-Multiple-Sclerosis.pdf
work_keys_str_mv AT persoelbergsørensen brainhealthtranslatingscientificevidenceintoclinicalpracticeinmultiplesclerosis
AT wiendl brainhealthtranslatingscientificevidenceintoclinicalpracticeinmultiplesclerosis
AT andreaslysandropoulos brainhealthtranslatingscientificevidenceintoclinicalpracticeinmultiplesclerosis
AT andrewchan brainhealthtranslatingscientificevidenceintoclinicalpracticeinmultiplesclerosis
_version_ 1725606645551071232